首页> 外文期刊>Experimental and clinical endocrinology and diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association >The Plasma Osteoprotegerin Level and Osteoprotegerin Expression in Renal Biopsy Tissue are Increased in Type 2 Diabetes with Nephropathy
【24h】

The Plasma Osteoprotegerin Level and Osteoprotegerin Expression in Renal Biopsy Tissue are Increased in Type 2 Diabetes with Nephropathy

机译:肾病的2型糖尿病患者肾活检组织中血浆骨保护素水平和骨保护素表达增加

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To investigate the plasma osteoprotegerin level and osteoprotegerin expression in renal biopsy tissue in type 2 diabetes with nephropathy. Methods: Plasma osteoprotegerin level was measured by enzyme- linked immunoassay in 48 type 2 diabetes with normoalbuminuria, 48 patients with microalbuminuria, 44 patients with macroalbuminuria and 40 healthy persons. Part of diabetes patients with nephropathy were performed kidney biopsy by ultrasound guide. The osteoprotegerin expression in kidney biopsy tissue is examined by immunohistochemistry. Results: The plasma osteoprotegerin levels were signifi cantly elevated in patients with microalbuminuria ( 3.73 0.75 ng/ l) and macroalbuminuria ( 4.68 0.82 ng/ l) as compared with patients with normoalbuminuria ( 2.71 0.69 ng/ l) and control subjects ( 2.11 0.42 ng/ l). And the plasma osteoprotegerin level in macroalbuminuric group was also higher than that in microalbuminuria group. The plasma osteopro-tegerin level had a positive correlation with the fasting plasma glucose ( FPG), 2- h plasma glucose ( 2hPG), glycohemoglobinA1c ( HbA1C), high sensitive C- reactive protein ( hsCRP) and log( UAER). Multivariate regression analysis revealed that plasma osteoprotegerin level was an independent factor associated with albuminuria in type 2 diabetes. The immunohistochemistry results showed that positive immunostaining for osteoprotegerin was observed in the renal tubule cells of biopsy and not in glomerulus, and the osteoprotegerin expression was higher in macroalbuminuria group than that in microalbuminuria group. Conclusions: The plasma osteoprotegerin level and the osteoprotegerin expression in renal tubule cells of biopsy tissue were increased in nephropathy of type 2 diabetes. This fi nding supports the growing concept that osteoprotegerin may act as an important regulatory molecule in the angiopathy, and particularly, that it may be involved in the occurrence and development of nephropathy in type 2 diabetes.
机译:目的:探讨2型糖尿病合并肾病肾活检组织中血浆血浆骨保护素水平和骨保护素表达。方法:采用酶联免疫法测定48例2型糖尿病伴正常白蛋白尿,48例微量白蛋白尿,44例大型白蛋白尿和40例健康人的血浆血浆骨保护素水平。通过超声引导对部分肾病糖尿病患者进行肾脏活检。通过免疫组织化学检查肾活检组织中的骨保护素表达。结果:微白蛋白尿(3.73 0.75 ng / l)和大白蛋白尿(4.68 0.82 ng / l)患者的血浆骨保护素水平显着高于正常白蛋白尿(2.71 0.69 ng / l)和对照组(2.11 0.42 ng) / l)。大型白蛋白尿组的血浆骨保护素水平也高于微量白蛋白尿组。血浆骨保护素水平与空腹血糖(FPG),2小时血浆葡萄糖(2hPG),糖化血红蛋白A1c(HbA1C),高敏感性C反应蛋白(hsCRP)和log(UAER)呈正相关。多元回归分析表明,血浆骨保护素水平是与2型糖尿病白蛋白尿相关的独立因素。免疫组织化学结果显示,在肾活检的肾小管细胞中观察到了骨保护素的阳性免疫染色,而在肾小球中则没有,并且蛋白尿的表达高于微量蛋白尿的组。结论:2型糖尿病肾病患者血浆中骨保护素水平和活检组织肾小管细胞中骨保护素表达均升高。这一发现支持了日益增长的观念,即骨保护素可能在血管病中起重要的调节分子的作用,尤其是它可能参与2型糖尿病肾病的发生和发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号